Spots Global Cancer Trial Database for antibody drug conjugate
Every month we try and update this database with for antibody drug conjugate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | NCT03384940 | Colorectal Neop... | DS-8201a | 18 Years - | Daiichi Sankyo | |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | NCT03474107 | Ureteral Cancer Urothelial Canc... Bladder Cancer | Enfortumab Vedo... Docetaxel Vinflunine Paclitaxel | 18 Years - | Astellas Pharma Inc | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | NCT03657043 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | tisotumab vedot... | 18 Years - | Seagen Inc. | |
| AMG 595 First-in-Human in Recurrent Gliomas | NCT01475006 | Advanced Malign... Anaplastic Astr... Glioblastoma Mu... | AMG 595 | 18 Years - | Amgen | |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | NCT03149549 | Solid Tumor, Ad... Breast Cancer Non Small Cell ... Head and Neck C... Ovarian Cancer | CX-2009 | 18 Years - | CytomX Therapeutics | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | NCT05329545 | High Grade Sero... Fallopian Tube ... Primary Periton... | Upifitimab rils... Placebo | 18 Years - | Mersana Therapeutics | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| Dose-escalation Study of Lupartumab Amadotin (BAY1129980) | NCT02134197 | Neoplasms | Lupartumab Amad... | 18 Years - | Bayer | |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | NCT04925284 | Non Small Cell ... Cervical Cancer SCCHN Pancreatic Canc... Esophageal SCC Metastatic Cast... Triple Negative... Hormone Recepto... Epithelial Ovar... Endometrial Can... Tissue Factor-E... | XB002 Nivolumab | 18 Years - | Exelixis | |
| Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02462525 | Multiple Myelom... | ABBV-838 Pomalidomide Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | NCT06422520 | Advanced Solid ... | BGB-C354 Tislelizumab | 18 Years - | BeiGene | |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02785900 | Acute Myeloid L... | 33A placebo azacitidine decitabine | 18 Years - | Seagen Inc. | |
| AMG 595 First-in-Human in Recurrent Gliomas | NCT01475006 | Advanced Malign... Anaplastic Astr... Glioblastoma Mu... | AMG 595 | 18 Years - | Amgen | |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | NCT05064358 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) | NCT02368951 | Medical Oncolog... | BAY1187982 | 18 Years - | Bayer | |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | NCT04460456 | HER2 Positive S... | SBT6050 pembrolizumab Cemiplimab | 18 Years - | Silverback Therapeutics | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | NCT03657043 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | tisotumab vedot... | 18 Years - | Seagen Inc. | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | NCT02908451 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Biliary Cancer | AbGn-107 | 18 Years - | AbGenomics B.V Taiwan Branch | |
| DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | NCT03384940 | Colorectal Neop... | DS-8201a | 18 Years - | Daiichi Sankyo | |
| A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression | NCT04610528 | Breast Cancer | U3 1402 U3 1402 | 18 Years - | SOLTI Breast Cancer Research Group | |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | NCT03149549 | Solid Tumor, Ad... Breast Cancer Non Small Cell ... Head and Neck C... Ovarian Cancer | CX-2009 | 18 Years - | CytomX Therapeutics | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | NCT05493683 | Colorectal Neop... | Disitamab vedot... Tislelizumab | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | NCT05511844 | HER2-positive B... HER-2 Protein O... HER-2 Gene Ampl... HER2 Gene Mutat... | ORM-5029 | 18 Years - | Orum Therapeutics USA, Inc. | |
| A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | NCT05629585 | Breast Cancer | Dato-DXd Durvalumab Capecitabine Pembrolizumab | 18 Years - 130 Years | AstraZeneca | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression | NCT04610528 | Breast Cancer | U3 1402 U3 1402 | 18 Years - | SOLTI Breast Cancer Research Group | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | NCT03386513 | Blastic Plasmac... Myeloproliferat... | IMGN632 | 18 Years - | ImmunoGen, Inc. | |
| Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | NCT03383692 | Neoplasm Metast... | DS-8201a Ritonavir Itraconazole | 20 Years - | Daiichi Sankyo | |
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia | NCT03957915 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Mixed Phenotype... | INA03 administr... | 18 Years - | Institut Paoli-Calmettes | |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | NCT05870748 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... Platinum-resist... | Luveltamab taze... Pegfilgrastim Gemcitabine Paclitaxel Pegylated lipos... Topotecan | 18 Years - | Sutro Biopharma, Inc. | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | NCT03255070 | Breast Neoplasm... Gastric Neoplas... Solid Tumors | ARX788 | 18 Years - | Ambrx, Inc. | |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | NCT04965766 | Metastatic Brea... | U3-1402 | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | NCT05870748 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... Platinum-resist... | Luveltamab taze... Pegfilgrastim Gemcitabine Paclitaxel Pegylated lipos... Topotecan | 18 Years - | Sutro Biopharma, Inc. | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | NCT04036461 | Multiple Myelom... | CC-99712 BMS-986405 | 18 Years - | Celgene | |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | NCT05511844 | HER2-positive B... HER-2 Protein O... HER-2 Gene Ampl... HER2 Gene Mutat... | ORM-5029 | 18 Years - | Orum Therapeutics USA, Inc. | |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
